Eculizumab treatment modifies the immune profile of PNH patients.

Authors: Alfinito, F  Ruggiero, G  Sica, M  Udhayachandran, A  Rubino, V  Della Pepa, R  Palatucci, AT  Annunziatella, M  Notaro, R  Risitano, AM  Terrazzano, G 
Citation: Alfinito F, etal., Immunobiology. 2012 Jul;217(7):698-703. doi: 10.1016/j.imbio.2011.11.009. Epub 2011 Dec 3.
Pubmed: (View Article at PubMed) PMID:22206707
DOI: Full-text: DOI:10.1016/j.imbio.2011.11.009

Paroxysmal Nocturnal Haemoglobinuria (PNH) is due to pathological expansion of a stem progenitor bearing a somatic mutation of PIG-A gene involved in the biosynthesis of the glycosyl-phosphatidyl-inositol (GPI) anchor. Numerous data suggest a role for immune-mediated mechanisms in the selection/expansion of GPI-defective clone. Haemolytic anaemia in PNH is dependent on the effect of complement against GPI-defective red cells. Eculizumab, an anti-C5 monoclonal antibody, is dramatically effective in controlling haemolysis and thrombosis, in reducing fatigue and in improving quality of life of patients. However, this therapy presents new challenges that need to be properly faced. Here, we report the decrease in B, Natural Killer (NK) and regulatory T cells (Treg), an altered cytokine profile of invariant-NKT cells (NKTi) and the increasing of C-X-C chemokine receptor type 4 (CXCR4) receptor in PNH patients before the Eculizumab therapy. Treatment significantly affects some of these alterations: after Eculizumab, the number of B lymphocytes, the cytokine secretion of NKTi and CXCR4 expression on CD8 T cells became similar to healthy donors. No effects were observed on NK and Treg. The amplitude of the GPI-defective compartment remained unchanged.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 11352266
Created: 2016-07-13
Species: All species
Last Modified: 2016-07-13
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.